GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (FRA:6IV) » Definitions » Cyclically Adjusted PS Ratio

Inventiva (FRA:6IV) Cyclically Adjusted PS Ratio : 7.00 (As of Dec. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inventiva Cyclically Adjusted PS Ratio?

As of today (2024-12-11), Inventiva's current share price is €2.38. Inventiva's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was €0.34. Inventiva's Cyclically Adjusted PS Ratio for today is 7.00.

The historical rank and industry rank for Inventiva's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:6IV' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.57   Med: 10   Max: 18.28
Current: 7.05

During the past 11 years, Inventiva's highest Cyclically Adjusted PS Ratio was 18.28. The lowest was 4.57. And the median was 10.00.

FRA:6IV's Cyclically Adjusted PS Ratio is ranked worse than
56.69% of 441 companies
in the Biotechnology industry
Industry Median: 6.1 vs FRA:6IV: 7.05

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Inventiva's adjusted revenue per share data of for the fiscal year that ended in Dec23 was €0.385. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.34 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Inventiva Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Inventiva's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva Cyclically Adjusted PS Ratio Chart

Inventiva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 13.89 12.18

Inventiva Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 13.89 - 12.18 -

Competitive Comparison of Inventiva's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Inventiva's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventiva's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Inventiva's Cyclically Adjusted PS Ratio falls into.



Inventiva Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Inventiva's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.38/0.34
=7.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Inventiva's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=0.385/118.3900*118.3900
=0.385

Current CPI (Dec23) = 118.3900.

Inventiva Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.327 99.860 0.388
201512 0.486 100.040 0.575
201612 0.600 100.650 0.706
201712 0.309 101.850 0.359
201812 0.156 103.470 0.178
201912 0.298 104.980 0.336
202012 0.011 104.960 0.012
202112 0.107 107.850 0.117
202212 0.294 114.160 0.305
202312 0.385 118.390 0.385

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inventiva  (FRA:6IV) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Inventiva Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Inventiva's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inventiva Business Description

Industry
Traded in Other Exchanges
Address
50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Inventiva Headlines

No Headlines